Which drug interaction should be prioritized for notification due to reduced antiplatelet effect when prescribing?

• A. Omeprazole interacts with clopidogrel to reduce the antiplatelet effect of clopidogrel
• B. Lisinopril with potassium supplement
• C. Metformin with contrast dye
• D. Simvastatin with warfarin

Answer: (A)

The main concept is that some drug combinations blunt the effect of antiplatelet therapy by blocking activation of a prodrug. Clopidogrel needs activation by the liver enzyme CYP2C19 to become effective. Omeprazole inhibits CYP2C19, so taking it with clopidogrel can lower the amount of active metabolite produced and reduce the antiplatelet effect. This can increase the risk of clotting events in patients who rely on clopidogrel for cardiovascular protection, making this interaction the one to notify about first.

The other options involve different safety concerns that do not directly reduce antiplatelet activity: lisinopril with a potassium supplement risks hyperkalemia; metformin with contrast dye raises kidney-related issues; and simvastatin with warfarin can affect anticoagulation but not the antiplatelet mechanism.